Oncorena
1 known investors
Oncorena is developing orellanine as a potential treatment for metastatic renal cell carcinoma and is running a clinical trial to evaluate its safety, tolerability, and anti-tumor efficacy in patients with metastatic clear-cell or papillary renal cell carcinoma. The company operates in oncology drug development for kidney cancer patients.